Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Technology appraisal guidance
Reference number: TA414
Published:
Please note that the first Appraisal Committee Meeting will take place on 17 May 2016. The second Appraisal Committee Meeting (if required) will take place on 19 July 2016.